More than 1000 NHS patients across the UK will be offered a new blood test to detect Alzheimer’s disease in a trial to assess their effectiveness. If approved the tests could form a pathway to accessing new drugs.
The Alzheimer’s disease diagnosis and plasma p-tau 217 (ADAPT) team—led by University College London (UCL) researchers Jonathan Schott and Ashvini Keshavan—is investigating the blood test that measures levels of p-tau217.
Alzheimer’s disease is the most common form of dementia, which is the leading cause of death in the UK.1 It is linked to a buildup of amyloid and tau proteins in the brain, with p-tau 217 a biomarker found in blood that can indicate the presence of both.
The test is designed to be used in addition to cognitive assessments in patients who have developed …
